Arcus Biosci 
Welcome,         Profile    Billing    Logout  
 0 Products   0 Diseases  0 Products   0 Trials   5 News 
99 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yutuo (zimberelimab) / Arcus Biosci, Gilead
ChiCTR2100054077: Efficacy and safety of Zimberelimab plus Lenvatinib as first-line treatment in unresectable or metastatic hepatocellular carcinoma patients: a single arm, prospective clinical study

Recruiting
4
32
 
Zimberelimab plus Lenvatinib
Jiansu Cancer Hospital; Jiansu Cancer Hospital, self-funded
Hepatocellular Carcinoma
 
 
ChiCTR2100053410: Single-arm, open, prospective clinical trail of Zimberelimab in combination with PARPi in patients with advanced solid tumors with homologous recombination defect (HRD)

Not yet recruiting
4
30
 
Zimberelimab combined with PARPi regimen
Xuzhou Central Hospital; Xuzhou Central Hospital, Self-financed
Advanced solid tumors with homologous recombination defect (HRD)
 
 
ChiCTR2300068673: Efficacy and safety of Zimberelimab combined with Chidamide and etoposide/gemcitabine in the treatment of peripheral T-cell lymphoma

Recruiting
4
20
 
Zimberelimab combined with Chidamide and etoposide/gemcitabine
Beijing Chaoyang Sanhuan Cancer Hospital; Beijing Chaoyang Sanhuan Cancer Hospital, Not yet
Peripheral T-cell lymphoma
 
 
ChiCTR2300068672: Efficacy and safety of Zimberelimab combined with Androtinib and chemotherapy in the treatment of recurrence/metastasis HNSCC.

Recruiting
4
20
 
Zimberelimab combine with Androtinib + Paclitaxel-albumin + Cisplatin/Carboplatin
Beijing Chaoyang Sanhuan Cancer Hospital; Beijing Chaoyang Sanhuan Cancer Hospital, Not yet
Head and neck squamous cell carcinoma
 
 
ChiCTR2200066669: A single-arm, prospective real-world clinical study of radiotherapy combined with Zimberelimab in the treatment of stage III-IVa nasopharyngeal carcinoma

Recruiting
4
20
 
radiotherapy combined with Zimberelimab
Second Affiliated Hospital of Xi'an Jiaotong University; Second Affiliated Hospital of Xi'an Jiaotong University, No
nasopharyngeal carcinoma
 
 
ChiCTR2400081017: Efficacy and safety of zimberelimab combined with chemoradiotherapy in the treatment of advanced cervical cancer

Not yet recruiting
4
30
 
Zimberelimab combine with chemoradiotherapy
Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital, None
Cervical cancer
 
 
ChiCTR2200064423: A prospective real-world clinical study of Zimberelimab(GLS-010) combined with induction chemotherapy followed by radical treatment for locally advanced or locally recurrent head and neck squamous cell carcinoma

Recruiting
4
100
 
Zimberelimab combined with cisplatin, 5-FU
Second Affiliated Hospital of Xi'an Jiaotong University; Second Affiliated Hospital of Xi'an Jiaotong University, None
Head and neck squamous cell carcinoma
 
 
2020-003562-39: Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Non-Small Cell Lung Cancer

Not yet recruiting
3
600
Europe
Zimberelimab, Domvanalimab, Carboplatin, Paclitaxel, Pemetrexed, AB122, AB154, Carboplatin, Paclitaxel, Pemetrexed, Concentrate for solution for infusion, Powder for concentrate for solution for infusion
Arcus Biosciences, Inc., Arcus Biosciences, Inc.
First Line Non-Small Cell Lung Cancer, First Line Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
2022-002222-27: A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastrointestinal tract cancer that cannot be removed with surgery that has spread to other parts of the body

Ongoing
3
970
Europe
Domvanalimab, Zimberelimab, OPDIVO, AB154, AB122, Concentrate for solution for infusion, OPDIVO
Arcus Biosciences, Inc., Arcus Biosciences Inc, Arcus Biosciences, Inc.
Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer, Diseases [C] - Cancer [C04]
 
 
2022-000578-25: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non–Small Cell Lung Cancer

Not yet recruiting
3
780
Europe
Zimberelimab, Domvanalimab, Pembrolizumab, GS-0122, Solution for infusion, Pembrolizumab
Gilead Sciences, Inc., GILEAD SCIENCES INCORPORATED, Gilead Sciences, Inc.
Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, Metastatic Non–Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
ARIAN, NCT06431633: Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Recruiting
3
129
Europe
Zimberelimab, anti-PD-1 monoclonal antibody AB122, Sacituzumab govitecan, Trodelvy, Cisplatin, Platinol, Carboplatin, Paraplatin
Fundación GECP
Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma
11/31
11/31
NCT05798819: A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Not yet recruiting
3
424
RoW
GLS-010, Placebo, paclitaxel, cisplatin, carboplatin, bevacizumab
Guangzhou Gloria Biosciences Co., Ltd.
Persistent, Recurrent, or Metastatic Cervical Cancer
05/25
12/26
NCT05518318: GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Not yet recruiting
3
60
NA
GLS-010, GLS-010 therapy, Chemotherapy of Investigator's choice
Guangzhou Gloria Biosciences Co., Ltd.
Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
06/25
06/25
STAR-221, NCT05568095 / 2022-002222-27: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Active, not recruiting
3
1040
Europe, Canada, Japan, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Arcus Biosciences, Inc., Gilead Sciences, Taiho Pharmaceutical Co., Ltd.
Advanced Upper Gastrointestinal Tract Adenocarcinoma
05/26
05/26
STAR-121, NCT05502237 / 2022-000578-25: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Active, not recruiting
3
792
Europe, Canada, Japan, US, RoW
Zimberelimab, GS-0122, AB122, Domvanalimab, GS-0154, AB154, Pembrolizumab, KEYTRUDA®, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Gilead Sciences, Arcus Biosciences, Inc.
Non-small Cell Lung Cancer
09/27
09/27
ChiCTR1800018042: Phase II study of GLS-010 injection in the treatment of classical Hodgkin's lymphoma

Recruiting
2
87
 
GLS-010
Beijing Cancer Hosptical; Beijing Cancer Hosptical, Guangzhou Gloria Biosciences Co. Ltd
classical Hodgkin's lymphoma
 
 
NCT03972722: Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

Checkmark Presentation of data in patients with PD-L1–positive recurrent or metastatic 2L cervical cancer at SITC 2022
Dec 2022 - Dec 2022: Presentation of data in patients with PD-L1–positive recurrent or metastatic 2L cervical cancer at SITC 2022
Recruiting
2
89
RoW
GLS-010, Full-human anti-pd-1 monoclonal antibodies
Guangzhou Gloria Biosciences Co., Ltd.
Cervical Cancer
05/22
05/23
2021-006291-16: A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal tract malignancies

Not yet recruiting
2
360
Europe
Domvanalimab, Zimberelimab, Quemliclustat, AB154, AB122, AB680, Solution for infusion, Lyophilisate for solution for infusion
Arcus Biosciences, Inc., Arcus Biosciences, Inc.
Advanced Upper Gastrointestinal Tract Malignancies, Upper Gastrointestinal Tract Cancer, Diseases [C] - Cancer [C04]
 
 
NCT05177770: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Terminated
2
16
Canada, US
SRF617, etrumadenant, AB928, zimberelimab, AB122
Coherus Biosciences, Inc., Arcus Biosciences, Inc., Surface Oncology
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
04/23
04/23
NCT06128460: Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.

Not yet recruiting
2
24
NA
Zimberelimab, Platinum, radiotherapy
Obstetrics & Gynecology Hospital of Fudan University
Cervical Cancer
12/25
12/29
ChiCTR2200066655: An observational clinical study on immunotherapy progress of Zimberelimab combined with Anlotnib in the treatment of advanced NSCLC

Recruiting
2
30
 
Zimberelimab combined with Anlotnib
Fuzhou First Hospital; Fuzhou First Hospital, PD1 monoclonal antibody was provided by Guangzhou Gloria Biosciences Co., Ltd.
non-smallcelllungcancer
 
 
ChiCTR2200060180: A noninterventionist registry study of a zimberelimab regimen in patients with advanced gastrointestinal tumors

Not yet recruiting
2
100
 
Treatment regimens containing Zimberelimab
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, self-funded
advanced gastrointestinal tumors
 
 
NCT06166589: Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Not yet recruiting
2
19
RoW
Zimberelimab, Oxaliplatin, S-1, Irinotecan
Shanghai Zhongshan Hospital
Previously AG Chemotherapy Treated Pancreatic Cancer
01/26
01/27
NCT06155396: A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Recruiting
2
116
RoW
Disitamab Vedotin, Disitamab Vedotin （RC48-ADC), Zimberelimab
RemeGen Co., Ltd.
Cervical Cancer
06/27
12/27
SBRT-AMICO, NCT05915442: Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Recruiting
2
23
US
Quemliclustat, AB680, Etrumadenant, AB928, Zimberelimab, AB122, Stereotactic Body Radiation Therapy, SBRT
Catherine Spina, Arcus Biosciences, Inc.
Oligometastatic Prostate Cancer
12/25
12/28
QUIC, NCT06048133: Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers

Recruiting
2
33
US
Gemcitabine, Cisplatin, Zimberelimab, AB122, Quemliclustat, AB680
Nataliya Uboha, Arcus Biosciences, Inc., Gilead Sciences, University of Wisconsin, Madison
Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
01/26
07/27
TROPHY-U-01, NCT03547973 / 2018-001167-23: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Hourglass Jun 2023 - Jun 2023 : Presentation of data from TROPHY U-01 trial for metastatic urothelial cancer at ASCO 2023
Checkmark Approved in US for 3L metastatic urothelial cancer
Apr 2021 - Apr 2021: Approved in US for 3L metastatic urothelial cancer
Checkmark Data from TROPHY U-01 trial for urothelial cancer at ESMO 2020
Sep 2020 - Sep 2020: Data from TROPHY U-01 trial for urothelial cancer at ESMO 2020
More
Recruiting
2
827
Europe, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, Pembrolizumab, KEYTRUDA®, Cisplatin, Avelumab, BAVENCIO®, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
Gilead Sciences, Merck KGaA, Darmstadt, Germany
Metastatic Urothelial Cancer
06/30
06/30
NCT05437692: Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

Recruiting
2
19
RoW
zimberelimab combined With concurrent radiotherapy and chemotherapy, GSL-010
Shanghai Zhongshan Hospital
Locally Advanced Cervical Cancer
07/24
07/25
RIGHT, NCT05540483: RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer

Recruiting
2
31
RoW
Disitamab Vedotin combined with Zimberelizumab, RC-48 combined with GLS-010
The First Affiliated Hospital with Nanjing Medical University
Biliary Carcinoma
08/24
08/25
ChiCTR2200057001: A prospective phase II clinical trial of the efficacy and safety of intracranial stereotactic radiotherapy (SRT) combined with zimberelimab (GLS-010) in the treatment of melanoma brain metastases

Not yet recruiting
2
11
 
Stereotactic radiotherapy (SRT) combined with zimberelimab (GLS-010)
Fujian Cancer Hospital; Fujian Cancer Hospital, Fujian Cancer Hospital
melanoma
 
 
ARC-10, NCT04736173 / 2020-003562-39: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Calendar Jan 2025 - Dec 2026: Data from ARC-10 trial for 1L PD-L1 NSCLC
Active, not recruiting
2
169
Europe, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
05/27
05/27
CZCNRHNSCC, NCT06107114: Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
52
RoW
Cetuximab, Zimberelimab, Docetaxel, Cisplatin
Xuekui Liu
Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
11/24
12/24
NCT04791839: Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Checkmark Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Dec 2022 - Dec 2022: Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Active, not recruiting
2
30
US
Zimberelimab, Domvanalimab, Etrumadenant
Washington University School of Medicine, Arcus Biosciences, Inc.
Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer
01/25
04/29
VELOCITY-HNSCC, NCT06727565: Study of Novel Treatment Combination Therapies in Participants with Head and Neck Squamous Cell Carcinoma.

Not yet recruiting
2
100
NA
Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin
Gilead Sciences, Arcus Biosciences, Inc.
Head and Neck Squamous Cell Carcinoma
08/26
08/26
preSAVE, NCT06528483: Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

Not yet recruiting
2
63
Europe
Sacituzumab Govitecan + Zimberelimab, TRODELVY, AB122
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Gilead Sciences
Bladder Cancer, Bladder Urothelial Carcinoma, Bladder Neoplasm, Muscle-Invasive Bladder Carcinoma
12/26
12/29
NCT05632848: Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Recruiting
2
47
RoW
Chidamide combined with Zimberelimab, Chidamide (Tucidinostat)
Sun Yat-sen University
Triple Negative Breast Cancer
12/24
12/25
NCT05130177: Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Recruiting
2
26
US
Zimberelimab, AB122, Domvanalimab, AB154
Diwakar Davar, Arcus Biosciences, Inc.
Melanoma
01/27
01/30
NCT06133517: PeRioperative Immunotherapy Combined with Sacituzumab Govitecan in Muscle Invasive BlAdder Cancer

Recruiting
2
70
Europe
Sacituzumab govitecan, Trodelvy, Zimberelimab, Domvanalimab
Fundación para el Progreso de la Oncología en Cantabria, Apices Soluciones S.L.
Urothelial Bladder Carcinoma
12/30
12/30
ARC-7, NCT04262856: Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Checkmark Interim data from ARC-7 trial in combination with zimberelimab for NSCLC at medical conference
May 2022 - May 2022: Interim data from ARC-7 trial in combination with zimberelimab for NSCLC at medical conference
Active, not recruiting
2
151
Canada, US, RoW
Domvanalimab, AB154, Etrumadenant, AB928, Zimberelimab, AB122
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
08/25
08/25
ZODIAC, NCT06250036: Peri-operative Zimberelimab vs Zimberelimab in Comb With Domvanalimab in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric & Gastro-oesophageal Junctional Adenocarcinoma

Recruiting
2
50
Europe
Single agent zimberelimab, Combination zimberelimab + domvanalimab
Royal Marsden NHS Foundation Trust, Gilead Sciences
Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
02/27
09/31
ChiCTR2300072293: An exploratory study on the first-line treatment of advanced unresectable soft tissue sarcoma with zimberelimab administered in combination with anlotinib and eribulin

Recruiting
2
30
 
zimberelimab administered in combination with anlotinib and eribulin
Sanhuan Cancer Hospital, Chaoyang District, Beijing; Sanhuan Cancer Hospital, selt-funded
soft tissue sarcoma
 
 
NCT05824468: Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Not yet recruiting
2
33
RoW
Zimberelimab, Anti-PD-1 antibody, Lenvatinib, Tyrosine Kinase Inhibitor
Sun Yat-sen University
Cervical Cancer, Cervical Carcinoma
06/25
06/26
NCT05900765: A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Recruiting
2
54
RoW
Zimberelimab 240mg, GLS-010
Sun Yat-sen University, Guangzhou Gloria Biosciences Co., Ltd.
Classical Hodgkin Lymphoma
06/25
06/26
ELEVATE HNSCC, NCT04854499 / 2020-005708-20: Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

Jan 2023 - Dec 2024: Data readout from trial in combination with Keytruda and chemotherapy for HNSCC
Terminated
2
193
Europe, US, RoW
Magrolimab, GS-4721, Pembrolizumab, KEYTRUDA®, Docetaxel, 5-FU, Cisplatin, Carboplatin, Zimberelimab
Gilead Sciences, Gilead Sciences, Inc.
Head and Neck Squamous Cell Carcinoma
10/24
10/24
STU-2022-1076, NCT05724563: Domvanalimab and Zimberelimab in Advanced Liver Cancers

Recruiting
2
58
US
Zimberelimab, AB122, Domvanalimab, AB154
University of Texas Southwestern Medical Center, Arcus Biosciences, Inc., Cancer Prevention Research Institute of Texas
Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma
07/26
06/27
EDGE-Gastric, NCT05329766 / 2021-006291-16: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Jan 2023 - Dec 2024: Data from ARC-21 trial for esophageal adenocarcinoma, gastroesophageal junction and gastric adenocarcinoma
Active, not recruiting
2
333
Europe, Canada, US, RoW
Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Arcus Biosciences, Inc., Gilead Sciences
Gastrointestinal Tract Malignancies
09/26
06/27
NCT05335941: A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Recruiting
2
20
US
Pemetrexed, LY23151, Alimta®, MTA, Multitargeted Antifolate, NSC-698037, Zimberelimab, AB122, Etrumadenant, AB928, Etruma
M.D. Anderson Cancer Center
Urothelial Carcinoma, Metastatic Cancer
09/25
09/25
PANTHER, NCT05024097: A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Recruiting
2
43
US
Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
Weill Medical College of Cornell University, Arcus Biosciences, Inc.
Rectal Cancer
12/25
12/30
NCT06009029: SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Not yet recruiting
2
96
NA
Stereotactic body radiation(SBRT), Zimberelimab (GLS-010), Immunotherapy
Peking University Third Hospital
Locally Advanced Pancreatic Cancer
07/26
07/27
EDGE-Lung, NCT05676931: Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Recruiting
2
400
Europe, US, RoW
Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet
Gilead Sciences, Arcus Biosciences, Inc.
Advanced Non-Small Cell Lung Cancer
12/27
12/27
NCT06055738: Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Recruiting
2
20
RoW
Zimberelimab, GLS-010, Albumin-bound Paclitaxel, Paclitaxel, Cisplatin, CDDP
Tang-Du Hospital
Locally Advanced Cervical Cancer
12/26
12/27
VELOCITY-Lung, NCT05633667: Study of Novel Treatment Combinations in Patients With Lung Cancer

Hourglass Jan 2024 - Dec 2024 : Data from substudy-1 of P2 VELOCITY-Lung trial for NSCLC in 2024
Recruiting
2
593
Europe, US, RoW
Zimberelimab (ZIM), AB122, GS-0122, Domvanalimab (DOM), AB154, GS-0154, Sacituzumab govitecan-hziy (SG), GS-0132, IMMU-132, Etrumadenant (ETRUMA), AB928, GS-0928, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
Gilead Sciences, Arcus Biosciences, Inc.
Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
01/27
01/27
ChiCTR2400084032: The efficacy and safety of second-line Zimberelimab and SIROX chemotherapy for patient with previously treated pancreatic cancer.

Not yet recruiting
2
36
 
Zimberelimab, 240mg, day1+Oxaliplatin 60mg/m2, day1day8+S-1(BSA < 1.2m2, 40 mg/day; BSA = 1.2~1.4 m2, 60 mg/day; BSA = 1.4~1.6 m2, 80 mg/day; BSA > 1.6 m2, 100 mg/day; bid, day1-14): Irinotecan, 130mg/m2, day 1, day 8. Every 3 weeks as a cycle.
Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Zhongshan Hospital Affiliated to Fudan University
Pancreatic cancer
 
 
AIRPanc, NCT06048484: Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting
2
60
US
Stereotactic body radiotherapy (SBRT), Zimberelimab, AB122, Quemliclustat, AB680, Etrumadenant, AB928, Modified FOLFIRINOX, mFOLFIRINOX
Gulam Manji, Arcus Biosciences, Inc.
Pancreatic Ductal Adenocarcinoma
04/27
04/27
NCT05886634: A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Recruiting
2
25
US
Etrumadenant, Zimberelimab
Memorial Sloan Kettering Cancer Center
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Recurrent Dedifferentiated Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma
05/27
05/27
NCT05872724: Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Recruiting
2
32
RoW
Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab, Chemoradiotherapy (small pelvic) + Zimberelimab
Suzhou Municipal Hospital
Cervical Cancer
01/28
12/28
2020-005386-13: A Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Estudio para evaluar la seguridad y la eficacia de combinaciones terapéuticas de AB928 en pacientes con cáncer colorrectal metastásico

Not yet recruiting
1/2
247
Europe
Etrumadenant, Zimberelimab, AB928, AB122, AB680, Capsule, hard, Concentrate for solution for infusion, Powder for injection
Arcus Biosciences, Inc., Arcus Biosciences Inc, Arcus Biosciences, Inc., ARCUS BIOSCIENCES INC
Metastatic colorectal cancer Cáncer colorrectal metastásico, Metastatic colorectal cancer Cáncer colorrectal metastásico, Diseases [C] - Cancer [C04]
 
 
ChiCTR1900023529: An open, multi-center, single-arm phase II clinical study for evaluating the efficacy and safety of recombinant fully human anti-PD-1 monoclonal antibody (GLS-010 injection) in patients with recurrent or metastatic cervical cancer

Not yet recruiting
1/2
89
 
GLS-010
Fudan University Shanghai Cancer Hospital; Guangzhou Gloria Biosciences Co., Ltd., Fully self-financing
recurrent or metastatic cervical cancer
 
 
ARC-9, NCT04660812 / 2020-005386-13: An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Jul 2023 - Dec 2023: Interim data from ARC-9 trial for metastatic colorectal cancer
Active, not recruiting
1/2
227
Europe, US, RoW
AB680, Etrumadenant, AB928, Zimberelimab, AB122, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib
Arcus Biosciences, Inc., Gilead Sciences
Metastatic Colorectal Cancer
07/25
07/25
ARC-6, NCT04381832: Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Hourglass Jul 2022 - Dec 2022 : Interim analysis data from ARC-6 trial in combination with Zimberelimab for castrate-resistant prostate cancer
Completed
1/2
173
Canada, US
Etrumadenant, AB928, Zimberelimab, AB122, Quemliclustat, AB680, Enzalutamide, Xtandi, Docetaxel, Taxotere, SG, Trodelvy
Arcus Biosciences, Inc., Gilead Sciences
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
08/24
08/24
MCC-21676, NCT06238921: Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Recruiting
1/2
31
US
Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan, Trodelvy
H. Lee Moffitt Cancer Center and Research Institute, Gilead Sciences
Breast Cancer, Triple Negative Breast Cancer
02/27
02/27
NCT05759312: Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma

Not yet recruiting
1/2
20
NA
Zimberelimab, Anti PD-1, Metformin Hydrochloride, Metformin
Fudan University
Ovarian Clear Cell Carcinoma
02/25
02/25
Triumph-02, NCT05978401: Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Not yet recruiting
1/2
152
RoW
GLS-012+GLS-010, LAG3, PD-1, GLS-012+GLS-010+pemetrexed+carboplatin, chemotherapy, GLS-012+GLS-010+paclitaxel+carboplatin
Guangzhou Gloria Biosciences Co., Ltd.
Advanced Non-Small Cell Lung Cancer
04/25
04/26
NCT05688215: Zimberelimab and Quemliclustat in Combination with Chemotherapy for the Treatment of Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Recruiting
1/2
56
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Core Biopsy, BIOPSY, CORE, CNB, Core Needle, Core Needle Biopsy, Needle Biopsy, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quemliclustat, AB 680, AB-680, AB680, CD73 Inhibitor AB680, Zimberelimab, AB 122, AB-122, AB122, Anti-PD-1 Monoclonal Antibody GLS-010, GLS 010, GLS-010, GLS010, WBP-3055
Jonsson Comprehensive Cancer Center, Arcus Biosciences, Inc.
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
05/25
05/26
NCT05419479: Switch Maintenance in Pancreatic

Recruiting
1/2
46
US
ZIMBERELIMAB, AB 122, DOMVANALIMAB, AB 154, APX005M, CD40, FOLFIRI
James Cleary, MD, PhD, Arcus Biosciences, Inc., Lustgarten Foundation
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
01/26
09/28
Triumph-01, NCT05909436: Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Recruiting
1/2
107
RoW
GLS-012, GLS-010
Guangzhou Gloria Biosciences Co., Ltd.
Solid Tumor
12/26
12/26
ChiCTR1800014425: A Phase I Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Recruiting
1
400
 
GLS-010
Beijing Cancer Hosptical; Harbin Gloria Pharmaceuticals Co., Ltd., Harbin Gloria Pharmaceuticals Co., Ltd.
Tumor
 
 
NCT03713905: Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Completed
1
293
RoW
GLS-010, Recombinant Human Anti-PD-1 Monoclonal Antibody
Guangzhou Gloria Biosciences Co., Ltd.
Advanced Solid Tumors
02/22
02/22
NCT05221775: Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Recruiting
1
18
RoW
Lenvatinib
Tianjin Medical University Cancer Institute and Hospital
First-line Treatment, Advanced Gastric Carcinoma
03/23
10/23
NCT04772989: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Active, not recruiting
1
94
Europe, US
AB308, Zimberelimab, AB122
Arcus Biosciences, Inc., Gilead Sciences
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
09/25
09/25
NCT03628677: A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Completed
1
75
US, RoW
Domvanalimab, AB154, Zimberelimab, AB122
Arcus Biosciences, Inc., Gilead Sciences
Solid Tumor, Unspecified, Adult
01/25
01/25
NCT04999761: AB122 Platform Study

Recruiting
1
917
Japan
AB122, TAS-116, TAS-120, TAS-115, TAS-102, Ramucirumab, Bevacizumab, Fluorouracil, Cisplatin, AB154, Carboplatin, nab-Paclitaxel, Gemcitabine
Taiho Pharmaceutical Co., Ltd.
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer, Biliary Tract Cancer
05/26
05/26
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
NCT06532565: Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Recruiting
1
154
Canada, US
GS-2121, Zimberelimab, GS-0122, AB122
Gilead Sciences
Advanced Solid Tumors
06/28
06/28
ARC-4, NCT03846310: A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Hourglass Feb 2022 - Jun 2022 : Initial data from trial for NSCLC
Completed
1
77
US, RoW
Etrumadenant, AB928, Zimberelimab, AB122, Carboplatin, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
11/24
11/24
NCT04087018: Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Completed
1
18
US
zimberelimab, AB122
Arcus Biosciences, Inc., Strata Oncology, Gilead Sciences
Advanced Solid Tumors
06/24
06/24
NCT06759649: A Clinical Trial to Assess COM503 in Participants with Advanced Solid Malignancies

Recruiting
1
200
US
COM503, Zimberelimab
Compugen Ltd, Gilead Sciences
Neoplasm, Cancer, Malignant Tumors
11/27
11/27
NCT04656535: AB154 Combined With AB122 for Recurrent Glioblastoma

Active, not recruiting
1
46
US
Zimberelimab, Domvanalimab, Placebo
Yale University, National Cancer Institute (NCI), Arcus Biosciences, Inc.
Glioblastoma
06/25
12/25
ARC-25, NCT05891171: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Recruiting
1
87
US, RoW
AB598, Zimberelimab, AB122, Fluorouracil, Leucovorin, Oxaliplatin
Arcus Biosciences, Inc.
Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
03/26
03/26
NCT05840224: Study of GS-4528 in Adults With Solid Tumors

Recruiting
1
182
Europe, Canada, US, RoW
GS-4528, Zimberelimab
Gilead Sciences
Solid Tumor
12/25
12/25
PANTHEoN, NCT04892875: A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Withdrawn
1
24
NA
Zimberelimab, AB122, Etrumadenant, AB928, Cisplatin, Radiation
Jennifer Choe, Arcus Biosciences, Inc.
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Larynx Cancer, Pharynx Cancer, Hypopharynx Cancer, Hypopharynx Squamous Cell Carcinoma
12/25
12/26
ARC-20, NCT05536141: A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Efficacy data from dose-expansion cohorts for ccRCC
Recruiting
1
302
US, RoW
casdatifan, AB521, Cabozantinib, Zimberelimab
Arcus Biosciences, Inc.
Clear Cell Renal Cell Carcinoma, Solid Tumors
07/27
07/27
NCT05007782: Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Recruiting
1
376
Europe, Canada, US, RoW
Denikitug, GS-1811, Zimberelimab
Gilead Sciences
Advanced Solid Tumor
12/27
12/27
NCT06082960: Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Recruiting
1
120
Canada, US, RoW
GS-9911, Zimberelimab
Gilead Sciences
Solid Tumors
11/26
11/26
ARC-27, NCT06120075: A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Recruiting
1
91
US, RoW
AB801, Docetaxel
Arcus Biosciences, Inc.
Advanced Cancer
11/26
11/26
ChiCTR2300078205: A retrospective study of zimberelimab in the treatment of recurrent and metastatic cervical cancer

Not yet recruiting
N/A
50
 
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University
cervical cancer
 
 
ChiCTR2200064398: Efficacy and safety of TP regimen combined with PD-1 monoclonal antibody as neoadjuvant therapy for locally advanced cervical cancer

Not yet recruiting
N/A
20
 
Zimberelimab
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology; Union Hopistal Tongji Medical College, Huazhong University of Science and Technolog, self-fundingrase
cervical carcinoma
 
 
ChiCTR2300071563: A phase Ⅱ study to evaluate the efficacy and safety of Surufatinib ,Zimberelimab combined with nab-paclitaxel in advanced triple-negative breast cancer

Recruiting
N/A
29
 
Surufatinib :250mg QD P.O, , Zimberelimab :360mg I.V D1 , , nab-paclitaxel:100mg/m2 I.V D1,D8.
Provincial Hospital Affiliated to Shandong First Medical University; Provincial Hospital Affiliated to Shandong First Medical University, Self-financing
TNBC
 
 
ChiCTR2300073629: An Exploratory Study of Zimberelimab Combined with Chemotherapy for Perioperative Treatment of Locally Advanced Resectable Gastric Cancer

Recruiting
N/A
30
 
zimberelimab combined with chemotherapy
Shandong Provincial Hospital; Shandong Provincial Hospital, self-funded
Locally Advanced Resectable Gastric Cancer
 
 
ChiCTR2300074055: Clinical study of zimberelimab combined with gemcitabine and albumin-paclitaxel in first-line treatment of patients with relapsed or metastatic pancreatic cancer

Recruiting
N/A
50
 
Patients will be treated with Zimberelimab combined with gemcitabine and albumin-paclitaxel. The dose of Zimberelimab was 360mg, Q3W. Gemcitabine was administrated through intravenous infusion longer than 30min at a dose of 1000mg/m2, Q3W. And dose of albumin-paclitaxel is 125mg/m2, Q3W, through intravenous infusion longer than 30min.
Shandong Provincial Hospital; Shandong Provincial Hospital, None
Recurrent or metastatic pancreatic cancer
 
 
ChiCTR2400081122: Dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of HN2201 injection as monotherapy or in combination with Zimberelimab for patients with advanced or recurrent HPV16 and/or 18+ cervical cancer after systemic treatment

Not yet recruiting
N/A
21
 
HN2201 injection; HN2201 +Zimberelimab Injection
Hunan Provincial Maternal and Child Health Care Hospital; Hunan Provincial Maternal and Child Health Care Hospital, Shenzhen magicRNA Biotechnology Co. ,LTD
Patients with advanced or recurrent HPV16 and/or 18+ cervical cancer who have failed to respond to standard treatment or are intolerant to standard treatment in the past
 
 
etrumadenant (AB928) / Arcus Biosci, Gilead
NCT03821246: Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Active, not recruiting
2
26
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Tocilizumab, Actemra, Etrumadenant, AB928
David Oh, Genentech, Inc.
Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
02/26
02/26
MORPHEUS-PDAC, NCT03193190 / 2016-004126-42: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hourglass Feb 2024 - Jun 2024 : Results from MORPHEUS-PDAC trial in 1L mPDAC
Checkmark In combination with BL-8040 for pancreatic ductal adenocarcinoma
Dec 2019 - Dec 2019: In combination with BL-8040 for pancreatic ductal adenocarcinoma
Active, not recruiting
1/2
340
Europe, Japan, US, RoW
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Hoffmann-La Roche
Pancreatic Adenocarcinoma
02/25
02/25
quemliclustat (AB680) / Arcus Biosci, Gilead
PRISM-1, NCT06608927: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
3
610
Europe, Japan, US, RoW
Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine
Arcus Biosciences, Inc., Taiho Pharmaceutical Co., Ltd.
Metastatic Pancreatic Ductal Adenocarcinoma
11/30
11/30
domvanalimab (AB154) / Arcus Biosci, Gilead
PACIFIC-8, NCT05211895 / 2021-004327-32: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with domvanalimab for stage 3 NSCLC (based on PACIFIC-8 trial)
Jan 2024 - Dec 2024: Data from PACIFIC-8 trial for NSCLC
Checkmark Initiated PACIFIC-8 trial in combination with durvalumab for stage 3 unresectable 2L NSCLC
Mar 2022 - Mar 2022: Initiated PACIFIC-8 trial in combination with durvalumab for stage 3 unresectable 2L NSCLC
Checkmark Initiation of PACIFIC-8 trial in combination with domvanalimab for Stage 3 NSCLC
More
Recruiting
3
860
Europe, Canada, Japan, US, RoW
Durvalumab, Domvanalimab, Placebo
AstraZeneca, Arcus Biosciences, Inc.
Non-Small Cell Lung Cancer
06/28
08/30
casdatifan (AB521) / Arcus Biosci
STELLAR-009, NCT06191796: Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors

Active, not recruiting
1/2
25
US
zanzalintinib, XL092, AB521, Nivolumab, OPDIVO®
Exelixis, Arcus Biosciences, Inc.
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
01/26
01/27
NCT05117554: Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

Completed
1
70
Europe
casdatifan, AB521, Placebo, Midazolam
Arcus Biosciences, Inc.
Healthy Participants
02/23
02/23
NCT05999513: A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

Completed
1
24
US
casdatifan, AB521
Arcus Biosciences, Inc.
Healthy Participants
10/23
10/23
AB801 / Arcus Biosci
NCT06004921: A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

Completed
1
32
Europe
AB801, Placebo
Arcus Biosciences, Inc.
Cancer
02/24
02/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yutuo (zimberelimab) / Arcus Biosci, Gilead
ChiCTR2100054077: Efficacy and safety of Zimberelimab plus Lenvatinib as first-line treatment in unresectable or metastatic hepatocellular carcinoma patients: a single arm, prospective clinical study

Recruiting
4
32
 
Zimberelimab plus Lenvatinib
Jiansu Cancer Hospital; Jiansu Cancer Hospital, self-funded
Hepatocellular Carcinoma
 
 
ChiCTR2100053410: Single-arm, open, prospective clinical trail of Zimberelimab in combination with PARPi in patients with advanced solid tumors with homologous recombination defect (HRD)

Not yet recruiting
4
30
 
Zimberelimab combined with PARPi regimen
Xuzhou Central Hospital; Xuzhou Central Hospital, Self-financed
Advanced solid tumors with homologous recombination defect (HRD)
 
 
ChiCTR2300068673: Efficacy and safety of Zimberelimab combined with Chidamide and etoposide/gemcitabine in the treatment of peripheral T-cell lymphoma

Recruiting
4
20
 
Zimberelimab combined with Chidamide and etoposide/gemcitabine
Beijing Chaoyang Sanhuan Cancer Hospital; Beijing Chaoyang Sanhuan Cancer Hospital, Not yet
Peripheral T-cell lymphoma
 
 
ChiCTR2300068672: Efficacy and safety of Zimberelimab combined with Androtinib and chemotherapy in the treatment of recurrence/metastasis HNSCC.

Recruiting
4
20
 
Zimberelimab combine with Androtinib + Paclitaxel-albumin + Cisplatin/Carboplatin
Beijing Chaoyang Sanhuan Cancer Hospital; Beijing Chaoyang Sanhuan Cancer Hospital, Not yet
Head and neck squamous cell carcinoma
 
 
ChiCTR2200066669: A single-arm, prospective real-world clinical study of radiotherapy combined with Zimberelimab in the treatment of stage III-IVa nasopharyngeal carcinoma

Recruiting
4
20
 
radiotherapy combined with Zimberelimab
Second Affiliated Hospital of Xi'an Jiaotong University; Second Affiliated Hospital of Xi'an Jiaotong University, No
nasopharyngeal carcinoma
 
 
ChiCTR2400081017: Efficacy and safety of zimberelimab combined with chemoradiotherapy in the treatment of advanced cervical cancer

Not yet recruiting
4
30
 
Zimberelimab combine with chemoradiotherapy
Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital, None
Cervical cancer
 
 
ChiCTR2200064423: A prospective real-world clinical study of Zimberelimab(GLS-010) combined with induction chemotherapy followed by radical treatment for locally advanced or locally recurrent head and neck squamous cell carcinoma

Recruiting
4
100
 
Zimberelimab combined with cisplatin, 5-FU
Second Affiliated Hospital of Xi'an Jiaotong University; Second Affiliated Hospital of Xi'an Jiaotong University, None
Head and neck squamous cell carcinoma
 
 
2020-003562-39: Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Non-Small Cell Lung Cancer

Not yet recruiting
3
600
Europe
Zimberelimab, Domvanalimab, Carboplatin, Paclitaxel, Pemetrexed, AB122, AB154, Carboplatin, Paclitaxel, Pemetrexed, Concentrate for solution for infusion, Powder for concentrate for solution for infusion
Arcus Biosciences, Inc., Arcus Biosciences, Inc.
First Line Non-Small Cell Lung Cancer, First Line Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
2022-002222-27: A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastrointestinal tract cancer that cannot be removed with surgery that has spread to other parts of the body

Ongoing
3
970
Europe
Domvanalimab, Zimberelimab, OPDIVO, AB154, AB122, Concentrate for solution for infusion, OPDIVO
Arcus Biosciences, Inc., Arcus Biosciences Inc, Arcus Biosciences, Inc.
Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer, Diseases [C] - Cancer [C04]
 
 
2022-000578-25: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non–Small Cell Lung Cancer

Not yet recruiting
3
780
Europe
Zimberelimab, Domvanalimab, Pembrolizumab, GS-0122, Solution for infusion, Pembrolizumab
Gilead Sciences, Inc., GILEAD SCIENCES INCORPORATED, Gilead Sciences, Inc.
Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, Metastatic Non–Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
ARIAN, NCT06431633: Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Recruiting
3
129
Europe
Zimberelimab, anti-PD-1 monoclonal antibody AB122, Sacituzumab govitecan, Trodelvy, Cisplatin, Platinol, Carboplatin, Paraplatin
Fundación GECP
Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma
11/31
11/31
NCT05798819: A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Not yet recruiting
3
424
RoW
GLS-010, Placebo, paclitaxel, cisplatin, carboplatin, bevacizumab
Guangzhou Gloria Biosciences Co., Ltd.
Persistent, Recurrent, or Metastatic Cervical Cancer
05/25
12/26
NCT05518318: GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Not yet recruiting
3
60
NA
GLS-010, GLS-010 therapy, Chemotherapy of Investigator's choice
Guangzhou Gloria Biosciences Co., Ltd.
Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
06/25
06/25
STAR-221, NCT05568095 / 2022-002222-27: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Active, not recruiting
3
1040
Europe, Canada, Japan, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Arcus Biosciences, Inc., Gilead Sciences, Taiho Pharmaceutical Co., Ltd.
Advanced Upper Gastrointestinal Tract Adenocarcinoma
05/26
05/26
STAR-121, NCT05502237 / 2022-000578-25: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Active, not recruiting
3
792
Europe, Canada, Japan, US, RoW
Zimberelimab, GS-0122, AB122, Domvanalimab, GS-0154, AB154, Pembrolizumab, KEYTRUDA®, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Gilead Sciences, Arcus Biosciences, Inc.
Non-small Cell Lung Cancer
09/27
09/27
ChiCTR1800018042: Phase II study of GLS-010 injection in the treatment of classical Hodgkin's lymphoma

Recruiting
2
87
 
GLS-010
Beijing Cancer Hosptical; Beijing Cancer Hosptical, Guangzhou Gloria Biosciences Co. Ltd
classical Hodgkin's lymphoma
 
 
NCT03972722: Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

Checkmark Presentation of data in patients with PD-L1–positive recurrent or metastatic 2L cervical cancer at SITC 2022
Dec 2022 - Dec 2022: Presentation of data in patients with PD-L1–positive recurrent or metastatic 2L cervical cancer at SITC 2022
Recruiting
2
89
RoW
GLS-010, Full-human anti-pd-1 monoclonal antibodies
Guangzhou Gloria Biosciences Co., Ltd.
Cervical Cancer
05/22
05/23
2021-006291-16: A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal tract malignancies

Not yet recruiting
2
360
Europe
Domvanalimab, Zimberelimab, Quemliclustat, AB154, AB122, AB680, Solution for infusion, Lyophilisate for solution for infusion
Arcus Biosciences, Inc., Arcus Biosciences, Inc.
Advanced Upper Gastrointestinal Tract Malignancies, Upper Gastrointestinal Tract Cancer, Diseases [C] - Cancer [C04]
 
 
NCT05177770: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Terminated
2
16
Canada, US
SRF617, etrumadenant, AB928, zimberelimab, AB122
Coherus Biosciences, Inc., Arcus Biosciences, Inc., Surface Oncology
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
04/23
04/23
NCT06128460: Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.

Not yet recruiting
2
24
NA
Zimberelimab, Platinum, radiotherapy
Obstetrics & Gynecology Hospital of Fudan University
Cervical Cancer
12/25
12/29
ChiCTR2200066655: An observational clinical study on immunotherapy progress of Zimberelimab combined with Anlotnib in the treatment of advanced NSCLC

Recruiting
2
30
 
Zimberelimab combined with Anlotnib
Fuzhou First Hospital; Fuzhou First Hospital, PD1 monoclonal antibody was provided by Guangzhou Gloria Biosciences Co., Ltd.
non-smallcelllungcancer
 
 
ChiCTR2200060180: A noninterventionist registry study of a zimberelimab regimen in patients with advanced gastrointestinal tumors

Not yet recruiting
2
100
 
Treatment regimens containing Zimberelimab
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, self-funded
advanced gastrointestinal tumors
 
 
NCT06166589: Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Not yet recruiting
2
19
RoW
Zimberelimab, Oxaliplatin, S-1, Irinotecan
Shanghai Zhongshan Hospital
Previously AG Chemotherapy Treated Pancreatic Cancer
01/26
01/27
NCT06155396: A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Recruiting
2
116
RoW
Disitamab Vedotin, Disitamab Vedotin （RC48-ADC), Zimberelimab
RemeGen Co., Ltd.
Cervical Cancer
06/27
12/27
SBRT-AMICO, NCT05915442: Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Recruiting
2
23
US
Quemliclustat, AB680, Etrumadenant, AB928, Zimberelimab, AB122, Stereotactic Body Radiation Therapy, SBRT
Catherine Spina, Arcus Biosciences, Inc.
Oligometastatic Prostate Cancer
12/25
12/28
QUIC, NCT06048133: Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers

Recruiting
2
33
US
Gemcitabine, Cisplatin, Zimberelimab, AB122, Quemliclustat, AB680
Nataliya Uboha, Arcus Biosciences, Inc., Gilead Sciences, University of Wisconsin, Madison
Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
01/26
07/27
TROPHY-U-01, NCT03547973 / 2018-001167-23: Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Hourglass Jun 2023 - Jun 2023 : Presentation of data from TROPHY U-01 trial for metastatic urothelial cancer at ASCO 2023
Checkmark Approved in US for 3L metastatic urothelial cancer
Apr 2021 - Apr 2021: Approved in US for 3L metastatic urothelial cancer
Checkmark Data from TROPHY U-01 trial for urothelial cancer at ESMO 2020
Sep 2020 - Sep 2020: Data from TROPHY U-01 trial for urothelial cancer at ESMO 2020
More
Recruiting
2
827
Europe, US, RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, Pembrolizumab, KEYTRUDA®, Cisplatin, Avelumab, BAVENCIO®, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
Gilead Sciences, Merck KGaA, Darmstadt, Germany
Metastatic Urothelial Cancer
06/30
06/30
NCT05437692: Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

Recruiting
2
19
RoW
zimberelimab combined With concurrent radiotherapy and chemotherapy, GSL-010
Shanghai Zhongshan Hospital
Locally Advanced Cervical Cancer
07/24
07/25
RIGHT, NCT05540483: RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer

Recruiting
2
31
RoW
Disitamab Vedotin combined with Zimberelizumab, RC-48 combined with GLS-010
The First Affiliated Hospital with Nanjing Medical University
Biliary Carcinoma
08/24
08/25
ChiCTR2200057001: A prospective phase II clinical trial of the efficacy and safety of intracranial stereotactic radiotherapy (SRT) combined with zimberelimab (GLS-010) in the treatment of melanoma brain metastases

Not yet recruiting
2
11
 
Stereotactic radiotherapy (SRT) combined with zimberelimab (GLS-010)
Fujian Cancer Hospital; Fujian Cancer Hospital, Fujian Cancer Hospital
melanoma
 
 
ARC-10, NCT04736173 / 2020-003562-39: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Calendar Jan 2025 - Dec 2026: Data from ARC-10 trial for 1L PD-L1 NSCLC
Active, not recruiting
2
169
Europe, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
05/27
05/27
CZCNRHNSCC, NCT06107114: Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
52
RoW
Cetuximab, Zimberelimab, Docetaxel, Cisplatin
Xuekui Liu
Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
11/24
12/24
NCT04791839: Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Checkmark Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Dec 2022 - Dec 2022: Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Active, not recruiting
2
30
US
Zimberelimab, Domvanalimab, Etrumadenant
Washington University School of Medicine, Arcus Biosciences, Inc.
Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer
01/25
04/29
VELOCITY-HNSCC, NCT06727565: Study of Novel Treatment Combination Therapies in Participants with Head and Neck Squamous Cell Carcinoma.

Not yet recruiting
2
100
NA
Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin
Gilead Sciences, Arcus Biosciences, Inc.
Head and Neck Squamous Cell Carcinoma
08/26
08/26
preSAVE, NCT06528483: Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

Not yet recruiting
2
63
Europe
Sacituzumab Govitecan + Zimberelimab, TRODELVY, AB122
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Gilead Sciences
Bladder Cancer, Bladder Urothelial Carcinoma, Bladder Neoplasm, Muscle-Invasive Bladder Carcinoma
12/26
12/29
NCT05632848: Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Recruiting
2
47
RoW
Chidamide combined with Zimberelimab, Chidamide (Tucidinostat)
Sun Yat-sen University
Triple Negative Breast Cancer
12/24
12/25
NCT05130177: Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Recruiting
2
26
US
Zimberelimab, AB122, Domvanalimab, AB154
Diwakar Davar, Arcus Biosciences, Inc.
Melanoma
01/27
01/30
NCT06133517: PeRioperative Immunotherapy Combined with Sacituzumab Govitecan in Muscle Invasive BlAdder Cancer

Recruiting
2
70
Europe
Sacituzumab govitecan, Trodelvy, Zimberelimab, Domvanalimab
Fundación para el Progreso de la Oncología en Cantabria, Apices Soluciones S.L.
Urothelial Bladder Carcinoma
12/30
12/30
ARC-7, NCT04262856: Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Checkmark Interim data from ARC-7 trial in combination with zimberelimab for NSCLC at medical conference
May 2022 - May 2022: Interim data from ARC-7 trial in combination with zimberelimab for NSCLC at medical conference
Active, not recruiting
2
151
Canada, US, RoW
Domvanalimab, AB154, Etrumadenant, AB928, Zimberelimab, AB122
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
08/25
08/25
ZODIAC, NCT06250036: Peri-operative Zimberelimab vs Zimberelimab in Comb With Domvanalimab in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric & Gastro-oesophageal Junctional Adenocarcinoma

Recruiting
2
50
Europe
Single agent zimberelimab, Combination zimberelimab + domvanalimab
Royal Marsden NHS Foundation Trust, Gilead Sciences
Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
02/27
09/31
ChiCTR2300072293: An exploratory study on the first-line treatment of advanced unresectable soft tissue sarcoma with zimberelimab administered in combination with anlotinib and eribulin

Recruiting
2
30
 
zimberelimab administered in combination with anlotinib and eribulin
Sanhuan Cancer Hospital, Chaoyang District, Beijing; Sanhuan Cancer Hospital, selt-funded
soft tissue sarcoma
 
 
NCT05824468: Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Not yet recruiting
2
33
RoW
Zimberelimab, Anti-PD-1 antibody, Lenvatinib, Tyrosine Kinase Inhibitor
Sun Yat-sen University
Cervical Cancer, Cervical Carcinoma
06/25
06/26
NCT05900765: A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Recruiting
2
54
RoW
Zimberelimab 240mg, GLS-010
Sun Yat-sen University, Guangzhou Gloria Biosciences Co., Ltd.
Classical Hodgkin Lymphoma
06/25
06/26
ELEVATE HNSCC, NCT04854499 / 2020-005708-20: Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

Jan 2023 - Dec 2024: Data readout from trial in combination with Keytruda and chemotherapy for HNSCC
Terminated
2
193
Europe, US, RoW
Magrolimab, GS-4721, Pembrolizumab, KEYTRUDA®, Docetaxel, 5-FU, Cisplatin, Carboplatin, Zimberelimab
Gilead Sciences, Gilead Sciences, Inc.
Head and Neck Squamous Cell Carcinoma
10/24
10/24
STU-2022-1076, NCT05724563: Domvanalimab and Zimberelimab in Advanced Liver Cancers

Recruiting
2
58
US
Zimberelimab, AB122, Domvanalimab, AB154
University of Texas Southwestern Medical Center, Arcus Biosciences, Inc., Cancer Prevention Research Institute of Texas
Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma
07/26
06/27
EDGE-Gastric, NCT05329766 / 2021-006291-16: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Jan 2023 - Dec 2024: Data from ARC-21 trial for esophageal adenocarcinoma, gastroesophageal junction and gastric adenocarcinoma
Active, not recruiting
2
333
Europe, Canada, US, RoW
Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Arcus Biosciences, Inc., Gilead Sciences
Gastrointestinal Tract Malignancies
09/26
06/27
NCT05335941: A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

Recruiting
2
20
US
Pemetrexed, LY23151, Alimta®, MTA, Multitargeted Antifolate, NSC-698037, Zimberelimab, AB122, Etrumadenant, AB928, Etruma
M.D. Anderson Cancer Center
Urothelial Carcinoma, Metastatic Cancer
09/25
09/25
PANTHER, NCT05024097: A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Recruiting
2
43
US
Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
Weill Medical College of Cornell University, Arcus Biosciences, Inc.
Rectal Cancer
12/25
12/30
NCT06009029: SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Not yet recruiting
2
96
NA
Stereotactic body radiation(SBRT), Zimberelimab (GLS-010), Immunotherapy
Peking University Third Hospital
Locally Advanced Pancreatic Cancer
07/26
07/27
EDGE-Lung, NCT05676931: Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Recruiting
2
400
Europe, US, RoW
Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet
Gilead Sciences, Arcus Biosciences, Inc.
Advanced Non-Small Cell Lung Cancer
12/27
12/27
NCT06055738: Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Recruiting
2
20
RoW
Zimberelimab, GLS-010, Albumin-bound Paclitaxel, Paclitaxel, Cisplatin, CDDP
Tang-Du Hospital
Locally Advanced Cervical Cancer
12/26
12/27
VELOCITY-Lung, NCT05633667: Study of Novel Treatment Combinations in Patients With Lung Cancer

Hourglass Jan 2024 - Dec 2024 : Data from substudy-1 of P2 VELOCITY-Lung trial for NSCLC in 2024
Recruiting
2
593
Europe, US, RoW
Zimberelimab (ZIM), AB122, GS-0122, Domvanalimab (DOM), AB154, GS-0154, Sacituzumab govitecan-hziy (SG), GS-0132, IMMU-132, Etrumadenant (ETRUMA), AB928, GS-0928, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
Gilead Sciences, Arcus Biosciences, Inc.
Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
01/27
01/27
ChiCTR2400084032: The efficacy and safety of second-line Zimberelimab and SIROX chemotherapy for patient with previously treated pancreatic cancer.

Not yet recruiting
2
36
 
Zimberelimab, 240mg, day1+Oxaliplatin 60mg/m2, day1day8+S-1(BSA < 1.2m2, 40 mg/day; BSA = 1.2~1.4 m2, 60 mg/day; BSA = 1.4~1.6 m2, 80 mg/day; BSA > 1.6 m2, 100 mg/day; bid, day1-14): Irinotecan, 130mg/m2, day 1, day 8. Every 3 weeks as a cycle.
Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Zhongshan Hospital Affiliated to Fudan University
Pancreatic cancer
 
 
AIRPanc, NCT06048484: Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting
2
60
US
Stereotactic body radiotherapy (SBRT), Zimberelimab, AB122, Quemliclustat, AB680, Etrumadenant, AB928, Modified FOLFIRINOX, mFOLFIRINOX
Gulam Manji, Arcus Biosciences, Inc.
Pancreatic Ductal Adenocarcinoma
04/27
04/27
NCT05886634: A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Recruiting
2
25
US
Etrumadenant, Zimberelimab
Memorial Sloan Kettering Cancer Center
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Recurrent Dedifferentiated Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma
05/27
05/27
NCT05872724: Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Recruiting
2
32
RoW
Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab, Chemoradiotherapy (small pelvic) + Zimberelimab
Suzhou Municipal Hospital
Cervical Cancer
01/28
12/28
2020-005386-13: A Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Estudio para evaluar la seguridad y la eficacia de combinaciones terapéuticas de AB928 en pacientes con cáncer colorrectal metastásico

Not yet recruiting
1/2
247
Europe
Etrumadenant, Zimberelimab, AB928, AB122, AB680, Capsule, hard, Concentrate for solution for infusion, Powder for injection
Arcus Biosciences, Inc., Arcus Biosciences Inc, Arcus Biosciences, Inc., ARCUS BIOSCIENCES INC
Metastatic colorectal cancer Cáncer colorrectal metastásico, Metastatic colorectal cancer Cáncer colorrectal metastásico, Diseases [C] - Cancer [C04]
 
 
ChiCTR1900023529: An open, multi-center, single-arm phase II clinical study for evaluating the efficacy and safety of recombinant fully human anti-PD-1 monoclonal antibody (GLS-010 injection) in patients with recurrent or metastatic cervical cancer

Not yet recruiting
1/2
89
 
GLS-010
Fudan University Shanghai Cancer Hospital; Guangzhou Gloria Biosciences Co., Ltd., Fully self-financing
recurrent or metastatic cervical cancer
 
 
ARC-9, NCT04660812 / 2020-005386-13: An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Jul 2023 - Dec 2023: Interim data from ARC-9 trial for metastatic colorectal cancer
Active, not recruiting
1/2
227
Europe, US, RoW
AB680, Etrumadenant, AB928, Zimberelimab, AB122, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib
Arcus Biosciences, Inc., Gilead Sciences
Metastatic Colorectal Cancer
07/25
07/25
ARC-6, NCT04381832: Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Hourglass Jul 2022 - Dec 2022 : Interim analysis data from ARC-6 trial in combination with Zimberelimab for castrate-resistant prostate cancer
Completed
1/2
173
Canada, US
Etrumadenant, AB928, Zimberelimab, AB122, Quemliclustat, AB680, Enzalutamide, Xtandi, Docetaxel, Taxotere, SG, Trodelvy
Arcus Biosciences, Inc., Gilead Sciences
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
08/24
08/24
MCC-21676, NCT06238921: Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Recruiting
1/2
31
US
Stereotactic Radiation, Zimberelimab, Sacituzumab govitecan, Trodelvy
H. Lee Moffitt Cancer Center and Research Institute, Gilead Sciences
Breast Cancer, Triple Negative Breast Cancer
02/27
02/27
NCT05759312: Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma

Not yet recruiting
1/2
20
NA
Zimberelimab, Anti PD-1, Metformin Hydrochloride, Metformin
Fudan University
Ovarian Clear Cell Carcinoma
02/25
02/25
Triumph-02, NCT05978401: Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Not yet recruiting
1/2
152
RoW
GLS-012+GLS-010, LAG3, PD-1, GLS-012+GLS-010+pemetrexed+carboplatin, chemotherapy, GLS-012+GLS-010+paclitaxel+carboplatin
Guangzhou Gloria Biosciences Co., Ltd.
Advanced Non-Small Cell Lung Cancer
04/25
04/26
NCT05688215: Zimberelimab and Quemliclustat in Combination with Chemotherapy for the Treatment of Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Recruiting
1/2
56
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Core Biopsy, BIOPSY, CORE, CNB, Core Needle, Core Needle Biopsy, Needle Biopsy, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quemliclustat, AB 680, AB-680, AB680, CD73 Inhibitor AB680, Zimberelimab, AB 122, AB-122, AB122, Anti-PD-1 Monoclonal Antibody GLS-010, GLS 010, GLS-010, GLS010, WBP-3055
Jonsson Comprehensive Cancer Center, Arcus Biosciences, Inc.
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
05/25
05/26
NCT05419479: Switch Maintenance in Pancreatic

Recruiting
1/2
46
US
ZIMBERELIMAB, AB 122, DOMVANALIMAB, AB 154, APX005M, CD40, FOLFIRI
James Cleary, MD, PhD, Arcus Biosciences, Inc., Lustgarten Foundation
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
01/26
09/28
Triumph-01, NCT05909436: Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Recruiting
1/2
107
RoW
GLS-012, GLS-010
Guangzhou Gloria Biosciences Co., Ltd.
Solid Tumor
12/26
12/26
ChiCTR1800014425: A Phase I Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Recruiting
1
400
 
GLS-010
Beijing Cancer Hosptical; Harbin Gloria Pharmaceuticals Co., Ltd., Harbin Gloria Pharmaceuticals Co., Ltd.
Tumor
 
 
NCT03713905: Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Completed
1
293
RoW
GLS-010, Recombinant Human Anti-PD-1 Monoclonal Antibody
Guangzhou Gloria Biosciences Co., Ltd.
Advanced Solid Tumors
02/22
02/22
NCT05221775: Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Recruiting
1
18
RoW
Lenvatinib
Tianjin Medical University Cancer Institute and Hospital
First-line Treatment, Advanced Gastric Carcinoma
03/23
10/23
NCT04772989: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Active, not recruiting
1
94
Europe, US
AB308, Zimberelimab, AB122
Arcus Biosciences, Inc., Gilead Sciences
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
09/25
09/25
NCT03628677: A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Completed
1
75
US, RoW
Domvanalimab, AB154, Zimberelimab, AB122
Arcus Biosciences, Inc., Gilead Sciences
Solid Tumor, Unspecified, Adult
01/25
01/25
NCT04999761: AB122 Platform Study

Recruiting
1
917
Japan
AB122, TAS-116, TAS-120, TAS-115, TAS-102, Ramucirumab, Bevacizumab, Fluorouracil, Cisplatin, AB154, Carboplatin, nab-Paclitaxel, Gemcitabine
Taiho Pharmaceutical Co., Ltd.
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer, Biliary Tract Cancer
05/26
05/26
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Recruiting
1
195
US
AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar
Arcus Biosciences, Inc.
Advanced Pancreatic Cancer
05/27
05/27
NCT06532565: Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Recruiting
1
154
Canada, US
GS-2121, Zimberelimab, GS-0122, AB122
Gilead Sciences
Advanced Solid Tumors
06/28
06/28
ARC-4, NCT03846310: A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Hourglass Feb 2022 - Jun 2022 : Initial data from trial for NSCLC
Completed
1
77
US, RoW
Etrumadenant, AB928, Zimberelimab, AB122, Carboplatin, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
11/24
11/24
NCT04087018: Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Completed
1
18
US
zimberelimab, AB122
Arcus Biosciences, Inc., Strata Oncology, Gilead Sciences
Advanced Solid Tumors
06/24
06/24
NCT06759649: A Clinical Trial to Assess COM503 in Participants with Advanced Solid Malignancies

Recruiting
1
200
US
COM503, Zimberelimab
Compugen Ltd, Gilead Sciences
Neoplasm, Cancer, Malignant Tumors
11/27
11/27
NCT04656535: AB154 Combined With AB122 for Recurrent Glioblastoma

Active, not recruiting
1
46
US
Zimberelimab, Domvanalimab, Placebo
Yale University, National Cancer Institute (NCI), Arcus Biosciences, Inc.
Glioblastoma
06/25
12/25
ARC-25, NCT05891171: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Recruiting
1
87
US, RoW
AB598, Zimberelimab, AB122, Fluorouracil, Leucovorin, Oxaliplatin
Arcus Biosciences, Inc.
Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
03/26
03/26
NCT05840224: Study of GS-4528 in Adults With Solid Tumors

Recruiting
1
182
Europe, Canada, US, RoW
GS-4528, Zimberelimab
Gilead Sciences
Solid Tumor
12/25
12/25
PANTHEoN, NCT04892875: A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Withdrawn
1
24
NA
Zimberelimab, AB122, Etrumadenant, AB928, Cisplatin, Radiation
Jennifer Choe, Arcus Biosciences, Inc.
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Larynx Cancer, Pharynx Cancer, Hypopharynx Cancer, Hypopharynx Squamous Cell Carcinoma
12/25
12/26
ARC-20, NCT05536141: A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Efficacy data from dose-expansion cohorts for ccRCC
Recruiting
1
302
US, RoW
casdatifan, AB521, Cabozantinib, Zimberelimab
Arcus Biosciences, Inc.
Clear Cell Renal Cell Carcinoma, Solid Tumors
07/27
07/27
NCT05007782: Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Recruiting
1
376
Europe, Canada, US, RoW
Denikitug, GS-1811, Zimberelimab
Gilead Sciences
Advanced Solid Tumor
12/27
12/27
NCT06082960: Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Recruiting
1
120
Canada, US, RoW
GS-9911, Zimberelimab
Gilead Sciences
Solid Tumors
11/26
11/26
ARC-27, NCT06120075: A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Recruiting
1
91
US, RoW
AB801, Docetaxel
Arcus Biosciences, Inc.
Advanced Cancer
11/26
11/26
ChiCTR2300078205: A retrospective study of zimberelimab in the treatment of recurrent and metastatic cervical cancer

Not yet recruiting
N/A
50
 
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University
cervical cancer
 
 
ChiCTR2200064398: Efficacy and safety of TP regimen combined with PD-1 monoclonal antibody as neoadjuvant therapy for locally advanced cervical cancer

Not yet recruiting
N/A
20
 
Zimberelimab
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology; Union Hopistal Tongji Medical College, Huazhong University of Science and Technolog, self-fundingrase
cervical carcinoma
 
 
ChiCTR2300071563: A phase Ⅱ study to evaluate the efficacy and safety of Surufatinib ,Zimberelimab combined with nab-paclitaxel in advanced triple-negative breast cancer

Recruiting
N/A
29
 
Surufatinib :250mg QD P.O, , Zimberelimab :360mg I.V D1 , , nab-paclitaxel:100mg/m2 I.V D1,D8.
Provincial Hospital Affiliated to Shandong First Medical University; Provincial Hospital Affiliated to Shandong First Medical University, Self-financing
TNBC
 
 
ChiCTR2300073629: An Exploratory Study of Zimberelimab Combined with Chemotherapy for Perioperative Treatment of Locally Advanced Resectable Gastric Cancer

Recruiting
N/A
30
 
zimberelimab combined with chemotherapy
Shandong Provincial Hospital; Shandong Provincial Hospital, self-funded
Locally Advanced Resectable Gastric Cancer
 
 
ChiCTR2300074055: Clinical study of zimberelimab combined with gemcitabine and albumin-paclitaxel in first-line treatment of patients with relapsed or metastatic pancreatic cancer

Recruiting
N/A
50
 
Patients will be treated with Zimberelimab combined with gemcitabine and albumin-paclitaxel. The dose of Zimberelimab was 360mg, Q3W. Gemcitabine was administrated through intravenous infusion longer than 30min at a dose of 1000mg/m2, Q3W. And dose of albumin-paclitaxel is 125mg/m2, Q3W, through intravenous infusion longer than 30min.
Shandong Provincial Hospital; Shandong Provincial Hospital, None
Recurrent or metastatic pancreatic cancer
 
 
ChiCTR2400081122: Dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of HN2201 injection as monotherapy or in combination with Zimberelimab for patients with advanced or recurrent HPV16 and/or 18+ cervical cancer after systemic treatment

Not yet recruiting
N/A
21
 
HN2201 injection; HN2201 +Zimberelimab Injection
Hunan Provincial Maternal and Child Health Care Hospital; Hunan Provincial Maternal and Child Health Care Hospital, Shenzhen magicRNA Biotechnology Co. ,LTD
Patients with advanced or recurrent HPV16 and/or 18+ cervical cancer who have failed to respond to standard treatment or are intolerant to standard treatment in the past
 
 
etrumadenant (AB928) / Arcus Biosci, Gilead
NCT03821246: Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Active, not recruiting
2
26
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Tocilizumab, Actemra, Etrumadenant, AB928
David Oh, Genentech, Inc.
Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
02/26
02/26
MORPHEUS-PDAC, NCT03193190 / 2016-004126-42: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hourglass Feb 2024 - Jun 2024 : Results from MORPHEUS-PDAC trial in 1L mPDAC
Checkmark In combination with BL-8040 for pancreatic ductal adenocarcinoma
Dec 2019 - Dec 2019: In combination with BL-8040 for pancreatic ductal adenocarcinoma
Active, not recruiting
1/2
340
Europe, Japan, US, RoW
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Hoffmann-La Roche
Pancreatic Adenocarcinoma
02/25
02/25
quemliclustat (AB680) / Arcus Biosci, Gilead
PRISM-1, NCT06608927: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
3
610
Europe, Japan, US, RoW
Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine
Arcus Biosciences, Inc., Taiho Pharmaceutical Co., Ltd.
Metastatic Pancreatic Ductal Adenocarcinoma
11/30
11/30
domvanalimab (AB154) / Arcus Biosci, Gilead
PACIFIC-8, NCT05211895 / 2021-004327-32: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with domvanalimab for stage 3 NSCLC (based on PACIFIC-8 trial)
Jan 2024 - Dec 2024: Data from PACIFIC-8 trial for NSCLC
Checkmark Initiated PACIFIC-8 trial in combination with durvalumab for stage 3 unresectable 2L NSCLC
Mar 2022 - Mar 2022: Initiated PACIFIC-8 trial in combination with durvalumab for stage 3 unresectable 2L NSCLC
Checkmark Initiation of PACIFIC-8 trial in combination with domvanalimab for Stage 3 NSCLC
More
Recruiting
3
860
Europe, Canada, Japan, US, RoW
Durvalumab, Domvanalimab, Placebo
AstraZeneca, Arcus Biosciences, Inc.
Non-Small Cell Lung Cancer
06/28
08/30
casdatifan (AB521) / Arcus Biosci
STELLAR-009, NCT06191796: Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors

Active, not recruiting
1/2
25
US
zanzalintinib, XL092, AB521, Nivolumab, OPDIVO®
Exelixis, Arcus Biosciences, Inc.
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
01/26
01/27
NCT05117554: Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

Completed
1
70
Europe
casdatifan, AB521, Placebo, Midazolam
Arcus Biosciences, Inc.
Healthy Participants
02/23
02/23
NCT05999513: A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

Completed
1
24
US
casdatifan, AB521
Arcus Biosciences, Inc.
Healthy Participants
10/23
10/23
AB801 / Arcus Biosci
NCT06004921: A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

Completed
1
32
Europe
AB801, Placebo
Arcus Biosciences, Inc.
Cancer
02/24
02/24

Download Options